bioAffinity Technologies, Inc.

bioAffinity Technologies develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other lung diseases using flow cytometry combined with machine learning analysis. The company's flagship product, CyPath® Lung, analyzes sputum samples to identify cancer-related cell populations and generates results within three days, offering high sensitivity and specificity alongside strong negative predictive value for small pulmonary nodules. bioAffinity generates revenue by performing these tests through its wholly owned CLIA-certified clinical laboratory, with established reimbursement codes and competitive economic advantages over alternative diagnostic approaches, while also developing a pipeline of companion diagnostics for asthma and chronic obstructive pulmonary disease, as well as novel cancer therapeutics.